This afternoon we watched Takeda Pharmaceutical drop -2.0% to a price of $14.82 per share. The Large-Cap Pharmaceutical company is now trading -12.48% below its average target price of $16.94. Analysts have set target prices ranging from $15.436461 to $18.812641 per share for Takeda Pharmaceutical, and have given the stock an average rating of buy.
The stock has a very low short interest at 0.2%, and a short ratio of 3.42. At 0.01%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a very small number of institutional investors are invested in the stock, with 2.3% of Takeda Pharmaceutical's shares being owned by this investor type.
Institutions Invested in Takeda Pharmaceutical
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Capital Research Global Investors | 0% | 13,201,004 | $195,704,881 |
| 2025-03-31 | Morgan Stanley | 0% | 5,702,524 | $84,539,917 |
| 2025-03-31 | Goldman Sachs Group Inc | 0% | 5,320,793 | $78,880,755 |
| 2025-03-31 | FMR, LLC | 0% | 3,865,098 | $57,300,077 |
| 2025-03-31 | Brandes Investment Partners L.P. | 0% | 3,504,142 | $51,948,904 |
| 2025-03-31 | Adage Capital Partners GP L.L.C. | 0% | 3,433,023 | $50,894,565 |
| 2025-03-31 | Renaissance Technologies, LLC | 0% | 3,157,700 | $46,812,901 |
| 2025-03-31 | First Trust Advisors LP | 0% | 2,755,955 | $40,857,032 |
| 2025-03-31 | Blackrock Inc. | 0% | 2,630,833 | $39,002,098 |
| 2025-03-31 | Van Eck Associates Corporation | 0% | 2,172,384 | $32,205,592 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Takeda Pharmaceutical.
